$3.14
0.16% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Savara, Inc. Stock price

$3.14
+0.09 2.79% 1M
+0.01 0.16% 6M
+0.07 2.12% YTD
-1.04 24.82% 1Y
+1.77 128.83% 3Y
+0.71 29.01% 5Y
-31.87 91.04% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.01 0.16%
ISIN
US8051111016
Symbol
SVRA
Sector
Industry

Key metrics

Market capitalization $541.84m
Enterprise Value $398.99m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.66
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-109.16m
Free Cash Flow (TTM) Free Cash Flow $-95.65m
Cash position $172.50m
EPS (TTM) EPS $-0.49
P/E forward negative
Short interest 11.84%
Show more

Is Savara, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Savara, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Savara, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Savara, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.28 0.28
27% 27%
-
-0.28 -0.28
27% 27%
-
- Selling and Administrative Expenses 28 28
60% 60%
-
- Research and Development Expense 80 80
54% 54%
-
-109 -109
55% 55%
-
- Depreciation and Amortization 0.28 0.28
27% 27%
-
EBIT (Operating Income) EBIT -109 -109
55% 55%
-
Net Profit -102 -102
58% 58%
-

In millions USD.

Don't miss a Thing! We will send you all news about Savara, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Savara, Inc. Stock News

Neutral
Business Wire
2 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS International Conference 2025. Data presented were from the Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP and demonstrated that molgramostim reduces surfactant burden ...
Neutral
Business Wire
7 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and provided a business update. “At the end of 1Q 2025, we announced the on-time submission of the MOLBREEVI BLA to the FDA for the treatment of autoimmune PAP and reques...
Neutral
Business Wire
8 days ago
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and present at the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference on May 20, 2025, at 4:30pm ET/1:30pm PT. The live webcast and subsequent replay will be ...
More Savara, Inc. News

Company Profile

Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.

Head office United States
CEO Matthew Pauls
Employees 59
Founded 1995
Website www.savarapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today